Clofibride

Biochem/physiol Actions Artepillin C analog 57 is a potent inhibitor of CREB-CRTC2 interaction that ameliorates metabolic syndrome in in obese mice. It suppresses CREB/CRTC2-mediated gluconeogenic and SREBP transcriptions.

A Cl-amidine derivative with greater cellular potency against PAD4 activity (EC₅₀ = 8.8 &microM, vs.

A Cl-amidine derivative with greater cellular potency against PAD4 activity (EC₅₀ = 8.8 &microM, vs.

Boc-Gly-Leu-OH.

Bococizumab (anti-PCSK9) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab (anti-PCSK9) can be used in the research of hypercholesterolemia.

Bococizumab (anti-PCSK9) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab (anti-PCSK9) can be used in the research of hypercholesterolemia.

Bococizumab (anti-PCSK9) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab (anti-PCSK9) can be used in the research of hypercholesterolemia.

Bococizumab (anti-PCSK9) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab (anti-PCSK9) can be used in the research of hypercholesterolemia.

General description This substance is supplied with certified chromatographic purity. The exact value can be found on the certificate.

BPKDi is a potent bipyridyl PKD inhibitor with IC50s of 1 nM, 9 nM and 1 nM for PKD1, PKD2 and PKD3, respectively. BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardiomyocytes

Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but &gt:240-fold against PDGFR-β.An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1.

Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but &gt:240-fold against PDGFR-β.An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1.